[1]
|
Wang, M., Herbst, R.S. and Boshoff, C. (2021) Toward Personalized Treatment Approaches for Non-Small-Cell Lung Cancer. Nature Medicine, 27, 1345-1356. https://doi.org/10.1038/s41591-021-01450-2
|
[2]
|
Duma, N., Santa-na-Davila, R. and Molina, J.R. (2019) Non-Small Cell Lung Cancer: Epidemiology, Screening, Diagnosis, and Treat-ment. Mayo Clinic Proceedings, 94, 1623-1640. https://doi.org/10.1016/j.mayocp.2019.01.013
|
[3]
|
Bray, F., Fer-lay, J., Soerjomataram, I., Siegel, R.L., Torre, L.A. and Jemal, A. (2018) Global Cancer Statistics 2018: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA: A Cancer Journal for Clinicians, 68, 394-424. https://doi.org/10.3322/caac.21492
|
[4]
|
Suda, K., Sato, K., Mizuuchi, H., Kobayashi, Y., Shimoji, M., Tomizawa, K., Takemoto, T., Iwasaki, T., Sakaguchi, M. and Mitsudomi, T. (2014) Recent Evidence, Advances, and Current Practices in Surgical Treatment of Lung Cancer. Respiratory Investigation, 52, 322-329. https://doi.org/10.1016/j.resinv.2014.06.003
|
[5]
|
韩莎莎, 等. 转移性非小细胞肺癌系统治疗[J]. 西北国防医学杂志, 2021, 42(5): 407-412.
|
[6]
|
郭超, 张家齐, 李单青. 非小细胞肺癌新辅助免疫治疗进展[J]. 中国肺癌杂志, 2022, 25(7): 524-533.
|
[7]
|
Nagano, T., Tachihara, M. and Nishimura, Y. (2019) Molecular Mechanisms and Tar-geted Therapies Including Immunotherapy for Non-Small Cell Lung Cancer. Current Cancer Drug Targets, 19, 595-630.
https://doi.org/10.2174/1568009619666181210114559
|
[8]
|
Larkin, J., Minor, D., D’Angelo, S., Neyns, B., et al. (2018) Overall Survival in Patients with Advanced Melanoma Who Received Nivolumab versus Investigator’s Choice Chemotherapy in CheckMate 037: A Randomized, Controlled, Open-Label Phase III Trial. Journal of Clinical Oncology, 36, 383-390. https://doi.org/10.1200/JCO.2016.71.8023
|
[9]
|
Rittmeyer, A., Barlesi, F., Waterkamp, D., Park, K., et al. (2017) Atezolizumab versus Docetaxel in Patients with Previously Treated Non-Small-Cell Lung Cancer (OAK): A Phase 3, Open-Label, Multicentre Randomised Controlled Trial. The Lancet, 389, 255-265. https://doi.org/10.1016/S0140-6736(16)32517-X
|
[10]
|
Brahmer, J.R., Lee, J.S., Ciuleanu, T.E., Bernabe Caro, R., et al. (2023) Five-Year Survival Outcomes with Nivolumab Plus Ipilimumab versus Chemotherapy as First-Line Treat-ment for Metastatic Non-Small-Cell Lung Cancer in CheckMate 227. Journal of Clinical Oncology, 41, 1200-1212. https://doi.org/10.1200/JCO.22.01503
|
[11]
|
Sung, H., Ferlay, J., Siegel, R.L., Laversanne, M., et al. (2021) Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA: A Cancer Journal for Clinicians, 71, 209-249. https://doi.org/10.3322/caac.21660
|
[12]
|
Cao, W., Chen, H.D., Yu, Y.W., et al. (2021) Changing Profiles of Cancer Burden Worldwide and in China: A Secondary Analysis of the Global Cancer Statistics 2020. Chinese Medical Journal (England), 134, 783-791.
https://doi.org/10.1097/CM9.0000000000001474
|
[13]
|
Chen, P., Liu, Y., Wen, Y. and Zhou, C. (2022) Non-Small Cell Lung Cancer in China. Cancer Communications (London), 42, 937-970. https://doi.org/10.1002/cac2.12359
|
[14]
|
Schreiber, R.D., Old, L.J. and Smyth, M.J. (2011) Cancer Immunoediting: Integrating Immunity’s Roles in Cancer Suppression and Promotion. Science, 331, 1565-1570. https://doi.org/10.1126/science.1203486
|
[15]
|
Chen, D.S. and Mellman, I. (2013) Oncology Meets Immunology: The Cancer-Immunity Cycle. Immunity, 39, 1-10.
https://doi.org/10.1016/j.immuni.2013.07.012
|
[16]
|
Socinski, M.A., Jotte, R.M., Cappuzzo, F., Nishio, M., et al. (2023) Association of Immune-Related Adverse Events with Efficacy of Atezolizumab in Patients with Non-Small Cell Lung Cancer: Pooled Analyses of the Phase 3 IMpower130, IMpower132, and IMpower150 Randomized Clinical Trials. JAMA Oncology, 9, 527-535.
https://doi.org/10.1001/jamaoncol.2022.7711
|
[17]
|
Zhou, F., Qiao, M. and Zhou, C. (2021) The Cutting-Edge Pro-gress of Immune-Checkpoint Blockade in Lung Cancer. Cellular & Molecular Immunology, 18, 279-293. https://doi.org/10.1038/s41423-020-00577-5
|
[18]
|
Kennedy, L.B. and Salama, A. (2020) A Review of Cancer Im-munotherapy Toxicity. CA: A Cancer Journal for Clinicians, 70, 86-104. https://doi.org/10.3322/caac.21596
|
[19]
|
Ai, L., Xu, A. and Xu, J. (2020) Roles of PD-1/PD-L1 Pathway: Signal-ing, Cancer, and beyond. Advances in Experimental Medicine and Biology, 1248, 33-59. https://doi.org/10.1007/978-981-15-3266-5_3
|
[20]
|
Han, Y., Liu, D. and Li, L. (2020) PD-1/PD-L1 Pathway: Cur-rent Researches in Cancer. American Journal of Cancer Research, 10, 727-742.
|
[21]
|
Hosseini, A., Gharibi, T., Marofi, F., et al. (2020) CTLA-4: From Mechanism to Autoimmune Therapy. International Immunopharmacology, 80, Article ID: 106221. https://doi.org/10.1016/j.intimp.2020.106221
|
[22]
|
李浩洋, 王敬慧. 晚期非小细胞肺癌免疫治疗进展[J]. 中国肺癌杂志, 2021, 24(2): 131-140.
|
[23]
|
Patel, S.A. and Weiss, J. (2020) Advances in the Treatment of Non-Small Cell Lung Cancer: Immunotherapy. Clinics in Chest Medicine, 41, 237-247. https://doi.org/10.1016/j.ccm.2020.02.010
|
[24]
|
Vansteenkiste, J., Wauters, E., Reymen, B., et al. (2019) Current Status of Immune Checkpoint Inhibition in Early-Stage NSCLC. Annals of Oncology, 30, 1244-1253. https://doi.org/10.1093/annonc/mdz175
|
[25]
|
Vaidya, P. and Cohen, E.E.W. (2019) Immunotherapy in Non-Small Cell Lung Cancer: Facts and Hopes. Clinical Cancer Research, 25, 4592-4602. https://doi.org/10.1158/1078-0432.CCR-18-1538
|
[26]
|
Garon, E.B., Rizvi, N.A., Hui, R., et al. (2015) Pembroli-zumab for the Treatment of Non-Small-Cell Lung Cancer. The New England Journal of Medicine, 372, 2018-2028. https://doi.org/10.1056/NEJMoa1501824
|
[27]
|
Herbst, R.S., Baas, P., Kim, D.W., Felip, E., et al. (2016) Pem-brolizumab versus Docetaxel for Previously Treated, PD-L1-Positive, Advanced Non-Small-Cell Lung Cancer (KEYNOTE-010): A Randomised Controlled Trial. The Lancet, 387, 1540-1550. https://doi.org/10.1016/S0140-6736(15)01281-7
|
[28]
|
Reck, M., Rodríguez-Abreu, D., Robinson, A.G., et al. (2016) Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer. The New England Journal of Medicine, 375, 1823-1833.
https://doi.org/10.1056/NEJMoa1606774
|
[29]
|
Reck, M., Rodríguez-Abreu, D., Robinson, A.G., et al. (2019) Up-dated Analysis of KEYNOTE-024: Pembrolizumab versus Platinum-Based Chemotherapy for Advanced Non-Small-Cell Lung Cancer with PD-L1 Tumor Proportion Score of 50% or Greater. Journal of Clinical Oncology, 37, 537-546. https://doi.org/10.1200/JCO.18.00149
|
[30]
|
Mok, T.S.K., Wu, Y.L., Kudaba, I., Kowalski, D.M., et al. (2019) Pembrolizumab versus Chemotherapy for Previously Untreated, PD-L1-Expressing, Locally Advanced or Metastatic Non-Small-Cell Lung Cancer (KEYNOTE-042): A Randomised, Open-Label, Controlled, Phase 3 Trial. The Lancet, 393, 1819-1830.
https://doi.org/10.1016/S0140-6736(18)32409-7
|
[31]
|
Brahmer, J., Reckamp, K.L., Baas, P., et al. (2015) Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer. The New England Journal of Medicine, 373, 123-135.
https://doi.org/10.1056/NEJMoa1504627
|
[32]
|
Larkin, J., Chiarion-Sileni, V., Gonzalez, R., et al. (2015) Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma. The New England Journal of Medicine, 373, 23-34. https://doi.org/10.1056/NEJMoa1504030
|
[33]
|
Nghiem, P.T., Bhatia, S., Lipson, E.J., et al. (2016) PD-1 Blockade with Pembrolizumab in Advanced Merkel-Cell Carcinoma. The New England Journal of Medicine, 374, 2542-2552. https://doi.org/10.1056/NEJMoa1603702
|
[34]
|
Powles, T., O’Donnell, P.H., Massard, C., et al. (2017) Efficacy and Safety of Durvalumab in Locally Advanced or Metastatic Urothelial Carcinoma: Updated Results from a Phase 1/2 Open-Label Study. JAMA Oncology, 3, e172411.
https://doi.org/10.1001/jamaoncol.2017.2411
|
[35]
|
Fehrenbacher, L., Spira, A., Ballinger, M., et al. (2016) Atezoli-zumab versus Docetaxel for Patients with Previously Treated Non-Small-Cell Lung Cancer (POPLAR): A Multicentre, Open-Label, Phase 2 Randomised Controlled Trial. The Lancet, 387, 1837-1846. https://doi.org/10.1016/S0140-6736(16)00587-0
|
[36]
|
Weinstock, C., Khozin, S., Suzman, D., et al. (2017) U.S. Food and Drug Administration Approval Summary: Atezolizumab for Metastatic Non-Small Cell Lung Cancer. Clinical Cancer Research, 23, 4534-4539.
https://doi.org/10.1158/1078-0432.CCR-17-0540
|
[37]
|
Weinmann, S.C. and Pisetsky, D.S. (2019) Mechanisms of Immune-Related Adverse Events during the Treatment of Cancer with Immune Checkpoint Inhibitors. Rheumatology (Oxford), 58, vii59-vii67.
https://doi.org/10.1093/rheumatology/kez308
|
[38]
|
Xu, C., Chen, Y.P., Du, X.J., et al. (2018) Comparative Safety of Immune Checkpoint Inhibitors in Cancer: Systematic Review and Network Meta-Analysis. BMJ, 363, k4226. https://doi.org/10.1136/bmj.k4226
|
[39]
|
Abdel-Wahab, N., Shah, M., Lopez-Olivo, M.A., et al. (2018) Use of Im-mune Checkpoint Inhibitors in the Treatment of Patients with Cancer and Preexisting Autoimmune Disease: A Systematic Review. Annals of Internal Medicine, 168, 121-130. https://doi.org/10.7326/M17-2073
|
[40]
|
Ramos-Casals, M., Brahmer, J.R., Callahan, M.K., et al. (2020) Immune-Related Adverse Events of Checkpoint Inhibitors. Nature Reviews Disease Primers, 6, Article No. 38. https://doi.org/10.1038/s41572-020-0160-6
|
[41]
|
John, T., Sakai, H., Ikeda, S., Cheng, Y., et al. (2022) First-Line Nivolumab plus Ipilimumab Combined with Two Cycles of Chemotherapy in Ad-vanced Non-Small Cell Lung Cancer: A Subanalysis of Asian Patients in CheckMate 9LA. International Journal of Clinical Oncology, 27, 695-706. https://doi.org/10.1007/s10147-022-02120-0
|
[42]
|
Tang, Q., Chen, Y., Li, X., Long, S., et al. (2022) The Role of PD-1/PD-L1 and Application of Immune-Checkpoint Inhibitors in Human Cancers. Frontiers in Immunology, 13, Article ID: 964442.
https://doi.org/10.3389/fimmu.2022.964442
|
[43]
|
Planchard, D., Popat, S., Kerr, K., et al. (2018) Metastatic Non-Small Cell Lung Cancer: ESMO Clinical Practice Guidelines for Diagnosis, Treatment and Follow-Up. Annals of Oncology, 29, iv192-iv237.
https://doi.org/10.1093/annonc/mdy275
|
[44]
|
Zhang, Y.X., Zhou, H.Q. and Zhang, L. (2018) Which Is the Optimal Immunotherapy for Advanced Squamous Non-Small-Cell Lung Cancer in Combination with Chemotherapy: Anti-PD-1 or Anti-PD-L1? The Journal for ImmunoTherapy of Cancer, 6, 135. https://doi.org/10.1186/s40425-018-0427-6
|
[45]
|
Cascone, T., William, W.N., Weissferdt, A., et al. (2021) Neoad-juvant Nivolumab or Nivolumab plus Ipilimumab in Operable Non-Small Cell Lung Cancer: The Phase 2 Randomized NEOSTAR Trial. Nature Medicine, 27, 504-514.
https://doi.org/10.1038/s41591-020-01224-2
|